PharmExec Blog

The Broken Clinical Research System

Dr. Greg Koski of the Alliance for Clinical Research Excellence and Safety (ACRES) talks to Moe Alsumidaie of Applied Clinical Trials about the urgent need for change in the clinical research industry.

Moe Alsumidaie: Can you tell me about the challenges that are facing the clinical trials industry?
Greg Koski: There are so many stakeholders working in the clinical trial enterprise, interacting, but often from within one silo to another. This gives the illusion of a unified system at work, but nothing could be farther from reality.

While there are a number of disciplined processes all developed by good people, there is limited interoperability and few well accepted industry-wide standards, even for critical processes. Additionally, the clinical trials endeavor is a very complex, competitive, and highly-regulated international environment. Many mission critical activities are conducted at study sites, but site performance is ‘challenged.’

This environment has created an ecosystem in which everyone is trying to preserve their own space and opportunities consequently, lacking transparency and collaboration. A shared space—a global clinical research collaborative network—could realize major benefits for all of the stakeholders. What we need is a comprehensive integrated system.

To address these challenges, ACRES, a not-for-profit collaborative operating in the public interest, is working to build a system that enables efficient and high-quality clinical trials for the betterment of the entire clinical research community and patients, something that is attainable through a global system but remains unrealized.

MA: Is clinical trial conduct ethical in its existing structure and model?
GK: I believe that most individuals and companies engaged in drug development and clinical research are good, well-intended ethical people. Medical products are not the same as most consumer products, such as cars and electronics, since we must use human subjects, often patients, as a means to an end to test safety and effectiveness.

Some would say that this is in itself unethical, but it is part of the “grand bargain” with society—to get safe, new drugs, we must study people, but we are also obligated to do such studies in a safe, quality and efficient manner.

Without a unified set of standards and processes, without a deeply embedded safety or quality culture, and without an integrated global system to house the elements necessary to ensure the safe conduct of ethical trials, we are failing to fulfill our ethical obligations, and frankly, we have experienced too many ethical lapses over the years.

The industry’s part of the bargain is to discover new therapeutics to benefit patients, to improve their lives and productivity, and since we fundamentally use patients in clinical research to the betterment of this end, we have an ethical obligation to conduct safe and efficient clinical trials in a professional manner.

As a multi-stakeholder collaborative industry-wide, we need to gather these pieces together, determine what more needs to be created or modified, and then integrate them into a fully functioning, complex but interconnected whole to ensure a healthy research environment, and then we need to keep making it better!

MA:  Is the industry ready for change?
GK: Ready or not, the industry must change, and it is changing dramatically. The industry is under enormous financial, regulatory, and ethical pressures, and the current approach does not support a sustainable enterprise. Suddenly, innovation and collaboration have become the by-words of the industry, and this newly found willingness to work together for change is very positive.

 

This entry was posted in Guest Blog, R&D and tagged , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

One Comment

  1. Grace DeVierno-Lipso
    Posted March 25, 2014 at 10:38 am | Permalink

    HERE IS A SOLUTION…just need a champion to inherit my vision and move it forward.I have no financial interest.

    Nurses have computer devices to coordinate medical information, but most nurses at the patient’s bedside and in the patient’s home lack internet access and social media tools. With nursing insights trapped, pharma loses a huge opportunity to improve health solutions.

    A GLOBAL vehicle that connects potentially 20,00,00 nurses at POINT OF CARE provides pharma a COST-EFFECTIVE method to LOCATE and SIGN UP CANDIDATES FOR CLINICAL TRIALS ANYWHERE IN THE WORLD. REAL-TIME nurse insights can be stored in the CLOUD, and the health industry will TRANSFORM how it uses nurse insights to construct and INSTILL TRUST IN EVIDENCED BASED solutions. *Electronic record data ? surveyed product information.

    One tool with four functions:

    1. Cost Effective Clinical Trial Recruitment Vehicle
    Researchers will have easy access to nurses at the patients’ bedside that can rapidly identify, and engage clinical trial candidates in hard to reach areas.
    2. Survey Tool
    Life science companies and doctors have the ability to access real-time insights from all, or a subset of nurses working in homes, hospitals, hospice, in a wide variety of specialties from around the world, on medication errors, non-compliance, and health-products.
    3. Engage Patients in Mobile Health
    Nurses can rate and improve the endless health-applications and integrate the most suitable in discharge instructions. Visiting nurses can monitor patients at home, and document factors that influence new products.
    4. Deliver Life Saving Information to Patients in Remote Areas
    Nurses have the ability to collaborate in and across organizations, provide oversight, and help colleagues using video conferencing, Skype, translate etc. This is critical in global disasters.

    BACKGROUND I have always tried to think of a way to end the nursing shortage in poor areas. I married an investor and realized entrepreneurs have incredible drive and want to save lives, but most lack relevant education and clinical experience.

    It dawned on me nurses could bring the missing trust, understanding, oversight, and stability to the health industry. Nurse insights emanating from the special nurse patient bond, round the clock care, will help innovators create great health products. In return, business would provide deserved remuneration to nurses who work in remote areas.

    I would be delighted to share more information and the GREAT progress so far. Grace RN gralip@aol.com

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta